Biomimetic nanoparticle-driven strategies for targeted drug delivery in glioblastoma
Source abstract
Abstract
Abstract Glioblastoma (GBM), the most prevalent primary brain tumor in adults, remains highly challenging due to its invasive nature, limited treatment effectiveness, and short median survival durations. Standard of care includes surgery, radiation, chemotherapy, and tumor treating fields; however, there has been little improvement in survival rates. Biomimetic nanoparticles (NPs), coated with cell membranes and endogenous components, have immense potential for improving chemotherapy in GBM, by imitating cellular architecture and eluding immune clearance. With more individualized and efficient drug delivery, immunotherapeutic approaches and biomimetic NPs may increase patient survival rates. This article summarizes the main research on biomimetic NPs for GBM therapy, focusing on the classification, mechanisms, advantages, and challenges, along with the advancements in the development of GBM vaccines.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Oronsky B, Reid TR, Oronsky A, Sandhu N, Knox SJ (2021) A review of newly diagnosed glioblastoma. Front Oncol 10:57401210.3389/fonc.2020.574012 ↗
2. Rong L, Li N, Zhang Z (2022) Emerging therapies for glioblastoma: current state and future directions. J Experimental Clin Cancer Res 410.1186/s13046-022-02349-7 ↗
3. Nørøxe DS, Poulsen HS, Lassen U (2016) Hallmarks of glioblastoma: a systematic review, vol 1. BMJ Publishing Group, ESMO Open
4. D’Alessio A, Proietti G, Sica G, Scicchitano BM (2019) Pathological and molecular features of glioblastoma and its peritumoral tissue. Cancers (Basel) 11(4):67–8910.3390/cancers11040469 ↗
5. Tan C, Wei Y, Ding X, Han C, Sun Z, Wang C (2022) Cell senescence-associated genes predict the malignant characteristics of glioblastoma. Cancer Cell Int 22(1):41110.1186/s12935-022-02834-1 ↗
6. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M (2020) Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 70(4):299–31210.3322/caac.21613 ↗
7. Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P (2012) Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 14(11):1316–2410.1093/neuonc/nos208 ↗
8. Ostrom QT, Adel Fahmideh M, Cote DJ, Muskens IS, Schraw JM, Scheurer ME et al (2019) Risk factors for childhood and adult primary brain tumors. Neuro Oncol 21(11):1357–137510.1093/neuonc/noz123 ↗
9. Smith C, Perfetti T, Chokshi C, Venugopal C, Ashford J, Singh S (2024) Risk factors for glioblastoma are shared by other brain tumor types. Hum Exp Toxicol 23:43
10. Gudbergsson JM, Christensen E, Kostrikov S, Moos T, Duroux M, Kjær A et al (2020) Conventional treatment of glioblastoma reveals persistent CD44(+) subpopulations. Mol Neurobiol 57(9):3943–395510.1007/s12035-020-02004-2 ↗
11. Chen Q, Tan K, Lin Q, Sarah N, Li-Wen Y, Heng S et al (2022) Nanotechnology: a better diagnosis and treatment strategy for brain tumour? J Young Investig 25(3):33–47
12. Shields LBE, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S et al (2015) Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Radiat Oncol 10(1):22210.1186/s13014-015-0527-0 ↗
13. Cruz JVR, Batista C, de Afonso BH, Alexandre-Moreira MS, Dubois LG, Pontes B et al (2022) Obstacles to glioblastoma treatment two decades after temozolomide. Cancers (Basel) 14(13):320310.3390/cancers14133203 ↗
14. Yang Y, Cheng N, Luo Q, Shao N, Ma X, Chen J et al (2023) How nanotherapeutic platforms play a key role in glioma? A comprehensive review of literature. Int J Nanomedicine 18(July):3663–369410.2147/IJN.S414736 ↗
15. Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y, Collis SJ (2021) Tumour treating fields therapy for glioblastoma: current advances and future directions. Br J Cancer 124(4):697–70910.1038/s41416-020-01136-5 ↗
16. Jain KK (2018) A critical overview of targeted therapies for glioblastoma. Front Oncol 8:41910.3389/fonc.2018.00419 ↗
17. Vaz-Salgado MA, Villamayor M, Albarrán V, Alía V, Sotoca P, Chamorro J, Rosero D, Barrill AM, Martín M, Fernandez E, Gutierrez JA (2023) Recurrent glioblastoma: a review of the treatment options. Cancers 15(17):427910.3390/cancers15174279 ↗
18. Birzu C, French P, Caccese M, Cerretti G, Idbaih A, Zagonel V et al (2020) Recurrent glioblastoma: from molecular landscape to new treatment perspectives. Cancers (Basel) 13(1):77–8910.3390/cancers13010047 ↗
19. Repurposed Drugs in Research for Cancer Clinical Trials - Pitavastatin. ClinicalTrials.gov. Identifier: NCT05977738. Accessed 18 Apr 2024
20. Surgical nivolumab and ipilimumab for recurrent GBM. ClinicalTrials.gov. Identifier: NCT04606316. Accessed 18 Apr 2024
21. A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma. ClinicalTrials.gov. Identifier: NCT02770378. Accessed 18 Apr 2024
22. Phase-1 study of folinic acid to modulate MGMT gene in glioblastoma. ClinicalTrials.gov. Identifier: NCT01700569. Accessed 18 Apr 2024
23. Pilot study of anlotinib with STUPP regimen for patients with newly diagnosed glioblastoma. ClinicalTrials.gov. Identifier: NCT04119674. Accessed 18 Apr 2024
24. Trial of Enzastaurin and bevacizumab in participants with recurrent malignant gliomas. ClinicalTrials.gov. Identifier: NCT00586508. Accessed 18 Apr 2024
25. A phase I study to investigate tolerability and efficacy of ALECSAT administered to glioblastoma multiforme patients. ClinicalTrials.gov. Identifier: NCT01588769. Accessed 18 Apr 2024
26. Efficacy and safety of imatinib mesylate plus hydroxyurea (HU) in patients with recurrent glioblastoma multiforme (GBM). ClinicalTrials.gov. Identifier: NCT00290771. Accessed 18 Apr 2024
27. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT). ClinicalTrials.gov. Identifier: NCT02977780. Accessed 18 Apr 2024.
28. Immunogene-modified T (IgT) cells against glioblastoma multiforme. ClinicalTrials.gov. Identifier: NCT03170141. Accessed 18 Apr 2024
29. Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme. ClinicalTrials.gov. Identifier: NCT01301430. Accessed on 18 Apr 2024
30. Dose-escalation study of carboplatin administration into the brain for glioblastoma multiforme. ClinicalTrials.gov. Identifier: NCT01317212. Accessed 18 Apr 2024
31. Biomarker-driven therapy using immune activators with nivolumab in patients with first recurrence of glioblastoma. ClinicalTrials.gov. Identifier: NCT03707457. Accessed 18 Apr 2024
32. Super-selective intraarterial intracranial infusion of bevacizumab (avastin) for glioblastoma multiforme. ClinicalTrials.gov. Identifier: NCT02285959. Accessed 18 Apr 2024
33. Pilot study of autologous chimeric switch receptor modified t cells in recurrent glioblastoma multiforme. ClinicalTrials.gov. Identifier: NCT02937844. Accessed 18 Apr 2024
34. Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D (2021) Pathogenetic features and current management of glioblastoma. Cancers 13(4):85610.3390/cancers13040856 ↗
35. Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C et al (2024) Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell 187(2):446-463.e1610.1016/j.cell.2023.12.013 ↗
36. Becker AP, Sells BE, Haque SJ, Chakravarti A (2021) Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology. Cancers 13(4):76110.3390/cancers13040761 ↗
37. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nature Commun 9(1):141010.1038/s41467-018-03705-y ↗
38. Denison TA, Bae YH (2012) Tumor heterogeneity and its implication for drug delivery. J Control Release 164(2):187–19110.1016/j.jconrel.2012.04.014 ↗
39. Wang R, Yan H, Yu A, Ye L, Zhai G (2021) Cancer targeted biomimetic drug delivery system. J Drug Delivery Sci Technol 63:10253010.1016/j.jddst.2021.102530 ↗
40. Al-Ostoot FH, Salah S, Khamees HA, Khanum SA (2021) Tumor angiogenesis: current challenges and therapeutic opportunities. Cancer Treat Res Commun 28:10042210.1016/j.ctarc.2021.100422 ↗
41. Tee D, Distefano J (2004) Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies. J Cancer Res Clin Oncol 1(130):15–2410.1007/s00432-003-0491-1 ↗
42. Lugano R, Ramachandran M, Dimberg A (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77(9):1745–177010.1007/s00018-019-03351-7 ↗
43. Singh N, Miner A, Hennis L, Mittal S (2021) Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist 4(1):17–43
44. Lim XY, Capinpin SM, Bolem N, Foo AS, Yip WC, Kumar AP, Teh DB (2023) Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme. Bioeng Transla Med 8(3):e1048310.1002/btm2.10483 ↗
45. Chen YX, Wei CX, Lyu YQ, Chen HZ, Jiang G, Gao XL (2020) Biomimetic drug-delivery systems for the management of brain diseases. Biomater Sci 8:1073–8810.1039/C9BM01395D ↗
46. van Solinge TS, Nieland L, Chiocca EA, Broekman MLD (2022) Advances in local therapy for glioblastoma — taking the fight to the tumour. Nat Rev Neurol 18:221–3610.1038/s41582-022-00621-0 ↗
47. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF et al (2016) Analysis of nanoparticle delivery to tumours. Nat Rev Mater 1:1601410.1038/natrevmats.2016.14 ↗
48. Alrushaid N, Khan FA, Al-Suhaimi EA, Elaissari A (2023) Nanotechnology in cancer diagnosis and treatment. Pharmaceutics 15(3):102510.3390/pharmaceutics15031025 ↗
49. Beh CY, Prajnamitra RP, Chen LL, Hsieh PCH (2021) Advances in biomimetic nanoparticles for targeted cancer therapy and diagnosis. Molecules 26(16):505210.3390/molecules26165052 ↗
50. Kim J, Cho H, Lim DK, Joo MK, Kim K (2023) Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors. Int J Mol Sci 24(12):1008210.3390/ijms241210082 ↗
51. Sharifi M, Cho WC, Ansariesfahani A, Tarharoudi R, Malekisarvar H, Sari S et al (2022) An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment. Cancers 14(12):286810.3390/cancers14122868 ↗
52. Manikkath J, Jishnu PV, Wich PR, Manikkath A, Radhakrishnan R (2022) Nanoparticulate strategies for the delivery of miRNA mimics and inhibitors in anticancer therapy and its potential utility in oral submucous fibrosis. Nanomedicine (Lond) 17(3):181–19510.2217/nnm-2021-0381 ↗
53. Manikkath J, Parekh HS, Mutalik S (2020) Surface-engineered nanoliposomes with lipidated and non-lipidated peptide-dendrimeric scaffold for efficient transdermal delivery of a therapeutic agent: development, characterization, toxicological and preclinical performance analyses. Eur J Pharm Biopharm 1(156):97–11310.1016/j.ejpb.2020.09.001 ↗
54. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–2510.1016/j.addr.2013.11.009 ↗
55. Dilliard SA, Siegwart DJ (2023) Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater 8(4):282–30010.1038/s41578-022-00529-7 ↗
56. Maeda H (2012) Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 9(88):53–7110.2183/pjab.88.53 ↗
57. Park J, Choi Y, Chang H, Um W, Ryu JH, Kwon IC (2019) Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics 9(26):8073–809010.7150/thno.37198 ↗
58. Prabhakar U, Maeda H, Jain KR, Sevick-Muraca EM, Zamboni W, Farokhzad OC et al (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73(8):2412–710.1158/0008-5472.CAN-12-4561 ↗
59. Mathew EN, Berry BC, Yang HW, Carroll RS, Johnson MD (2022) Delivering therapeutics to glioblastoma: overcoming biological constraints. Int J Mol Sci 23(3):171110.3390/ijms23031711 ↗
60. Zhang M, Du Y, Wang S, Chen B (2020) A review of biomimetic nanoparticle drug delivery systems based on cell membranes. Drug Design, Dev Ther 14:5495–50310.2147/DDDT.S282368 ↗
61. Li YJ, Wu JY, Liu J, Qiu X, Xu W, Tang T et al (2021) From blood to brain: blood cell-based biomimetic drug delivery systems. Drug Deliv 28(1):1214–122510.1080/10717544.2021.1937384 ↗
62. Yang R, Wei T, Goldberg H, Wang W, Cullion K, Kohane DS (2017) Getting drugs across biological barriers. Adv Mater 29(37):160659610.1002/adma.201606596 ↗
63. Liu J, Cabral H, Mi P (2024) Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release. Adv Drug Delivery Rev 207:11523910.1016/j.addr.2024.115239 ↗
64. Azizi M, Jahanban-Esfahlan R, Samadian H, Hamidi M, Seidi K, Dolatshahi-Pirouz A, Shahbazi MA (2023) Multifunctional nanostructures: intelligent design to overcome biological barriers. Materials Today Bio 20:10067210.1016/j.mtbio.2023.100672 ↗
65. Patra JK, Das G, Fraceto LF, Campos EVR, del Rodriguez-Torres MP, Acosta-Torres LS et al (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology 16(1):7110.1186/s12951-018-0392-8 ↗
66. Hu D, Xia M, Wu L, Liu H, Chen Z, Xu H et al (2023) Challenges and advances for glioma therapy based on inorganic nanoparticles. Mater Today Bio 20:10067310.1016/j.mtbio.2023.100673 ↗
67. Zhang M, Gao S, Yang D, Fang Y, Lin X, Jin X et al (2021) Influencing factors and strategies of enhancing nanoparticles into tumors in vivo. Acta Pharm Sin B 11(8):2265–228510.1016/j.apsb.2021.03.033 ↗
68. Lu B, Wang J, Hendriks AJ, Nolte TM (2023) Clearance of nanoparticles from blood: effects of hydrodynamic size and surface coatings. Environ Sci Nano 11(1):406–41710.1039/D3EN00812F ↗
69. Gupta T, Sahoo RK, Singh H, Katke S, Chaurasiya A, Gupta U (2023) Lipid-based nanocarriers in the treatment of glioblastoma multiforme (GBM): challenges and opportunities. AAPS PharmSciTech 24(4):10710.1208/s12249-023-02555-2 ↗
70. Han X, Gong C, Yang Q, Zheng K, Wang Z, Zhang W (2024) Biomimetic nano-drug delivery system: an emerging platform for promoting tumor treatment. Int J Nanomedicine 19:571–60810.2147/IJN.S442877 ↗
71. Kadry H, Noorani B, Cucullo L (2020) A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17(1):6910.1186/s12987-020-00230-3 ↗
72. Daneman R, Prat A (2015) The blood-brain barrier. Cold Spring Harb Perspect Biol 7(1):a02041210.1101/cshperspect.a020412 ↗
73. Brown LS, Foster CG, Courtney JM, King NE, Howells DW, Sutherland BA (2019) Pericytes and neurovascular function in the healthy and diseased brain. Front Cell Neurosci 13(June):1–9
74. Yalamarty SSK, Filipczak N, Li X, Subhan MA, Parveen F, Ataide JA et al (2023) Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM). Cancers (Basel) 15(7):211610.3390/cancers15072116 ↗
75. Marcucci F, Corti A, Ferreri AJM (2021) Breaching the blood–brain tumor barrier for tumor therapy. Cancers 13(10):239110.3390/cancers13102391 ↗
76. Onishi M, Kurozumi K, Ichikawa T, Date I (2013) Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Neurol Med Chir (Tokyo) 53(11):755–76310.2176/nmc.ra2013-0200 ↗
77. Dubois LG, Campanati L, Righy C, D’Andrea-Meira I, Spohr TCL de S e, Porto-Carreiro I et al (2014) Gliomas and the vascular fragility of the blood-brain barrier. Front Cell Neurosci 8:41810.3389/fncel.2014.00418 ↗
78. Qiu Z, Yu Z, Xu T, Wang L, Meng N, Jin H, Xu B (2022) Novel nano-drug delivery system for brain tumor treatment. Cells 11(23):376110.3390/cells11233761 ↗
79. Mi P, Cabral H, Kataoka K (2020) Ligand-installed nanocarriers toward precision therapy, vol 32. Wiley-VCH Verlag, Advanced Materials
80. Lin YJ, Wei KC, Chen PY, Lim M, Hwang TL (2021) Roles of neutrophils in glioma and brain metastases. Front Immunol 12(August):1–19
81. Xue J, Zhao Z, Zhang L, Xue L, Shen S, Wen Y et al (2017) Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol 12(7):692–70010.1038/nnano.2017.54 ↗
82. Li J, Zeng H, Li L, Song M, Dong M (2023) Biomembrane-wrapped gene delivery nanoparticles for cancer therapy. Front Bioeng Biotechnol 11(June):1–17
83. Fu S, Liang M, Wang Y, Cui L, Gao C, Chu X et al (2019) Dual-modified novel biomimetic nanocarriers improve targeting and therapeutic efficacy in glioma. ACS Appl Mater Interfaces 11(2):1841–185410.1021/acsami.8b18664 ↗
84. Liu Y, Luo J, Chen X, Liu W, Chen T (2019) Cell membrane coating technology: a promising strategy for biomedical applications. Nano-Micro Lett 11:1–46. https://doi.org/10.1007/s40820-019-0330-910.1007/s40820-019-0330-9 ↗
85. Gerstner ER, Batchelor TT (2012) Antiangiogenic therapy for glioblastoma. Cancer J 18(1):45–5010.1097/PPO.0b013e3182431c6f ↗
86. Zhao Z, Wang D, Li Y (2023) Versatile biomimetic nanomedicine for treating cancer and inflammation disease. Med Rev 3(2):123–5110.1515/mr-2022-0046 ↗
87. Madhankumar AB, Mrowczynski OD, Patel SR, Weston CL, Zacharia BE, Glantz MJ et al (2017) Interleukin-13 conjugated quantum dots for identification of glioma initiating cells and their extracellular vesicles. Acta Biomater 58:205–21310.1016/j.actbio.2017.06.002 ↗
88. Zein R, Sharrouf W, Selting K (2020) Physical properties of nanoparticles that result in improved cancer targeting. Journal of Oncology 2020(1):5194780
89. Yuan BO, Zhao Y, Dong S, Sun Y, Hao F, Xie J et al (2019) Cell-penetrating peptide-coated liposomes for drug delivery across the blood-brain barrier. Anticancer Res 39(1):237–24310.21873/anticanres.13103 ↗
90. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674(1):171–17410.1016/0006-8993(95)00023-J ↗
91. Mendanha D, Vieira de Castro J, Ferreira H, Neves NM (2021) Biomimetic and cell-based nanocarriers – new strategies for brain tumor targeting. J Controlled Release 337(March):482–9310.1016/j.jconrel.2021.07.047 ↗
92. Al-Hetty HRAK, Kadhim MS, Al-Tamimi JHZ, Ahmed NM, Jalil AT, Saleh MM et al (2023) Implications of biomimetic nanocarriers in targeted drug delivery. Emergent Mater 6(1):1–1310.1007/s42247-023-00453-8 ↗
93. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM (2018) Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 18(7):452–46410.1038/s41568-018-0005-8 ↗
94. Dong Y, Liao H, Yu J, Fu H, Zhao D, Gong K et al (2019) Incorporation of drug efflux inhibitor and chemotherapeutic agent into an inorganic/organic platform for the effective treatment of multidrug resistant breast cancer. J Nanobiotechnology 17(1):12510.1186/s12951-019-0559-y ↗
95. Wang T, Zhang H, Qiu W, Han Y, Liu H, Li Z (2022) Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy. Bioact Mater 16:418–432
96. Al-Hetty HRAK, Kadhim MS, Al-Tamimi JHZ, Ahmed NM, Jalil AT, Saleh MM et al (2023) Implications of biomimetic nanocarriers in targeted drug delivery. Emergent Mater 6(1):1–1310.1007/s42247-023-00453-8 ↗
97. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y et al (2020) Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 7(August):1–14
98. Manikkath J, Sumathy TK, Manikkath A, Mutalik S (2018) Delving deeper into dermal and transdermal drug delivery: factors and mechanisms associated with nanocarrier-mediated strategies. Curr Pharm Des 24(27):3210–3222. https://doi.org/10.2174/1381612824666180924122640. (PMID: 30246632)10.2174/1381612824666180924122640 ↗
99. Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135–14610.1016/j.jconrel.2010.08.027 ↗
100. Manikkath J, Subramony JA (2021) Toward closed-loop drug delivery: integrating wearable technologies with transdermal drug delivery systems. Adv Drug Deliv Rev 179:11399710.1016/j.addr.2021.113997 ↗